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Blood sera of patients with autoimmune diseases soleroderma @cl), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) have been 
shown to yield a specific immune response to topoisomerase I, the product of expression of a cDNA fragment cloned into lZgtl1 and monoclonal 
antibodies (MAB) to the enzyme. The ‘topoisomerase t st’ is no1 absolutely specific for Scl. The stable positive response of autoimmune sera to 
anti-topoisomerase monoclonal antibodies bus a specific haracter and is associated with the interaction of the Fab fragment of MAB krith the 
IgG fraction of autoimmune serum. The response observed indicates the induction of anti-idiotypic antibodies against topoisomerase. The 
anti-idiotype, isolated by HPLC and affinity chromatography demonstrated the following functional activities: (i) the lnnnunologicol reaction 
against DNA; (ii) high-affinity DNA-binding with topoisomernse-s@lk consensus; (iii) ability to compete with the native enzyme for biding 
with DNA and MAB to topoisomerase; (iv) immunological reaction against MAB to topoisomerase. 
Autoimmunity; Topoisomcrase I; Antiidiotypic antibody; Fusion protein; MPLC of autoimmune sera 
Production of specific antibodies against various 
physiologically active compounds, their precursors, 
transient state analogs and biopolymers has recently 
gained a new stimulating aspect and entered another 
phase due to the development of a special field of im- 
munochemistry and enzymology, viz. the catalysis by 
antibodies or ‘abzymcs’ [l,Z] which has wide prospects 
for use both in fundamental research and for practical 
purposes. 
Marked progress in the new field of abzymes has been 
so far achieved regarding only a limited number of bio- 
logically significant chemical transformations and 
mostly concerns chemistry of proteolysis 131. To our 
knowledge, for example, one of the most interesting 
objects, DNA, has not been considered yet as an anti- 
body substrate. Many difficulties in this field are con- 
nected with the problem ofchoosing an adequate model 
for DNA chemical transformations and a design of the 
corresponding transient states. 
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A specific feature of our approach is an attempt to 
discover naturally occurring anti-DNA antibodies pos- 
sessing an enhanced specificity for certain sequences. 
Identification of such antibodies and investigation of 
their properties would provide prerequisites for analyz- 
ing the nature of their specificity and possible involve- 
ment in catalytic reactions. 
2. MATERIALS AND METHODS 
2.1. Antigen-antibody Znteruction 
Quantitative analysis of antigen-antibody interaction was oar&d 
out by the ELISA method [4]. 
2.2. Topoisonterase 1 
Topoisomerase I was obtained by the HPLC method as described 
earlier [5J 
2.3. C/or&g and cx~ression 01 the human lopoisomerase I gene 
P3 (see Fig. 1) is a fusion protein, expressed from a cDNA fragmenl 
cloned in ;tstl 1 vector, which was obtained by i.rnmunos~reening 5 x 
lo5 reoombinant clones of a human placenta cDNA library using 
autoimmunc Scl seta, biotinylated anti-human antibodies, and avidin- 
proxldaae conjugate as a non-isotope detection system [&I. 
2.4. Isolution of antibodies to ropoisomsrase Iancfpwparation of FAB- 
fragments 
Monoolonal antibodies against topoisomeraso I were obtained by 
the method described earlier [7]. Fab-fragments were Prepared by 
’ Pro-mo:jszs yL .eu Y1l).-...- -r Gf% -~l-~Aw with nnn& 33 me Fab fraction was . . . . . r_r 
purified with NPLC chromatography on a TSK-3000 SW gel-hitra- 
tion column (21.6 x GO0 nun) by elution with buff& A at a flow rate 
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of 0.2 ml/min. The peak of elution of the Fab-fragment corresponded 
to a molecular weight of 50 kDa. 
Homogeneity was proved with SDS-PAGE according to Laemmli 
[9], using a 12.5% gel under reducing conditions. MW of FAB-frag- 
ment corresponds to SO kDa. 
2.5. Arrroanribadies prepatarion 
All patients with SC!, SLE and RA were examined in the clinic at 
the lnstitutc of Rheumatology, Academy of Medical Science. The 
diagnosis was confirmed nnd its relidbilily checked using the criteria 
developed by rhc American Rheumatoid Association. The sera of 34 
patients with Scl (14), SLE (7) and RA (13) were analysed. 
Separation ofautoimmune scra involvd: (i) precipitation with 40% 
(NH,),SCJ,,; (ii} HPLC separation on a TSK G 3000 SW gel-filtration 
column as described above; (iii) 1gG fractions, exhibiting a positive 
rcsponsc to DNA and MAB to topoisomcrnse I by the ELISA lest 
were divided into two parts. One was applied to a dsDNA_cellulose 
column (Sigma, USA) in buffer A (10 mM K-phosphate, 100 mM 
NaCI, pH 72). The chromatography was performed using an increas- 
ing gradient of K-phosphate from 10 mM to I M, pH 7.3 for 40 min 
at a flow rate 2 ml/min. The second part was separated on BrCN- 
Srpharosc (Biolar, USSR), coupled with MAB to topoisomerase. 
Modification was carried out in the mixture: IO mg antibodies, 0.5 g 
scphorosc per ml of 0. I M NaHCO, buffer, pH 9.0, with nirring for 
14 h. Remaining groups were blocked with 0. I M Tris-HCI buffer, pH 
9.0, at 4 h. The adsorbrnt was subsequcnlly washed with 2 M NaCl 
in Tris-HCI buffer, pll 7.5, and 0.1 M glycinc-HCI buffer, pH 3.0. 
Non-specific adsorption was blocked with 10% fetal serum. And- 
idioiypcs werr applied to the column in buffer A, washed with the 
same buffer and elutcd with 0.1 M glycinc-HC1 buffer, pH 2.5, col- 
Ieccted fractions being neutmlized with 0.5 M Tris-I-ICI, pH 7.5, follow- 
ed by dialysis against buffer A. Immunological properties of anti- 
idiolypcs as anti-DNA and an&MAB antibodies were analysed by 
ELISA-test. A standard kit was used for anti-DNA antibodies meas- 
urements (Biolar, USSR). 
26 Assays of conprririorl of copoisott~erasc and cmri-idiotype~’ for 
Topoisomerasr was adsorbed onto a plale at a concentration of 0.1 
,ugfml. Varying amounts of anti-idiotypes were incubated with bioti. 
nylatcd MAB at a constimt concentration of 30 ydml, overnight at 
4OC. The mixture was re-applicul to the plate and the avidin-peroxi- 
dasc conjugate was added to develop the colour reaction. Using this 
technique, only the specific internction of free MAB (anti-idiotypc 
unbound) with topoisomemsc is determined. 
2.7. DNA-binding of cznri-icliocypes aucl ropoisonurase I 
The fragment of dsDNA from 3’-il* globin gene, labclcd at the 
S-end, containing different potential sites for topoisomernse binding 
[IO] was incubated with 20 U of lopoisomerasc I or I pg of an& 
idiotypic antibodies for 20 min at 37OC (concentration of a fragment 
was from 0.5 to 50 ng&l); 20 pg of poly dAT was added to exclude 
non-specific binding. The incubation mixture contained 20 mM Tris- 
HCI, pW 7.5, 50 mM KCI, 3 mM CaCI,, 0. I M sucrose, I mM DTT. 
The reaction mixture was applied to wet nitroccllulose filters and 
washed three times for 2 min with the same buiY&. The radioactivity 
was measured in a scintillation counter. As a, control, a mixture of 
5’-lab&d DNA wilh l-2 mg l3SA was used. Using the resuhing data, 
the constant was determined by the method of Lineweaver-Burk. 
3. RESULTS AND DISCUSSION 
In our investigation of DNA-specific antibodies we 
examined sera from patients with autoimmune diseases. 
This pathology is known to be characterized by the 
accumulation in the patients’ blood of substantial 
amounts of autoantibodies against antigens of the nu- 
cleoprotein type [ll]. Earlier it was shown that the 
blood of patients with some forms of Scl had an in- 
creased titer of antibodies against one of the key en- 
zymes of DNA metabolism, topoisomerase I [12]. 
Immunoscreening of the human placenta cDNA li- 
brary in the expression ilgtll vector revealed clones 
expressing topoisomerase I in the fusion protein with 
galactosidase. The DNA structure of the isolated clones 
was compared with the data of D’Arpa et al. [13] (see 
Fig. 1). The analysis of 34 patients having different 
autoimmune pathologies (see Table I) demonstrated 
that the sera from some patients with Scl, SLE and RA 
yielded a high stable positive response to the cloned 
topoisomerase-galactosidase fusion protein (fragment 
P3, Fig. 1). So, the recombinant protein can successfully 
substitute the native enzyme in immunological studies 
as a diagnostic test for autoimmune diseases. However, 
unlike the results reported by other investigators [14], 
we have found that apart from 100% positive reactions 
observed in the case of Scl, the sera from patients with 
SLE and RA also happen to be immunogenic with re- 
spect to topoisomarase. Therefore, the ‘topoisomerase 
test’ does not appear specific exclusively for Scl. 
Since the recognitior. system in the case of autoimmu- 
nity is characterized ‘t’y the spontaneous induction of 
the second antibodies in the series of the suggested anti- 
idiotypic network [l5], it was reasonable to search for 
specific antibodies against DNA among anti-idiotypic 
antibodies against topoisomerase. We have analyzed all 
Table I 
Positive immune response of the blood sera from patients with autoimmunc diseases to the expressed topoisomerase-galactosidase fusion protein 
and anti-topoisomerase monoclonal antibodies (MAB) 
Autoimmune disease Number oT patients Absoluie values (%) 
Fusion protein Monoclonal amibodies : Fusion protein -t- monoclonal 
(MAD) antibodies (MAD) 
SLE 14 8 ( 57.1) 7 (50.0) 4 (28.5) 
RR I3 II ( 84.6) 9 (B9.2) 8 (61 S) 
Scl 7 7 (100.0) 6 (35.7) 6 (85.7) 
The interaclion of MAB with blood scra wns analyzed by the ELISA method using MABs to membrane proteins of the potato virus as the negative 
control. The result exceeding the background by 100% was considered reliable. The serum dilution used was l:lOO. 
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I 
Human topo t cRNA 3646 bp 
I 
r p3 2330 &p I 
603 Qly Cye Cy8 Ser beu Arg Val Glu Wla Ble 617 
S-Sau3A 
H-Hindlll 
E-EcoRI 
Fig. 1. Human topoisamcrasc I cDNA map. P3 contains regions 
coding for the protein fragments responsible for the catalytic function 
[ti] and for the binding of the produced monoclonal antibodies against 
the calf thymus enzyme. TIE region n,din3 for LIE conscrvativc 
polypcptidc ommon for different DNA binding proteilxs i  indicated 
by arrows [18]. 
the available sera for monoclonal antibodies to topoi- 
somerase I which effectively interacted with the ex- 
pressed fusion protein (dissociation constant, deter- 
mined by the Scatchard method [l#] was below 5.7 nM). 
Some of the studied sera had a high stable positive 
response both to topoisomerase and the monoclonal 
A 
antibodies against it. An especially high level of re- 
sponse was observed from the serum of patients with 
rheumatoid arthritis. Partially HFLC-purified autoim- 
mune serum (see Fig. 2) was found to possess the same 
property. We had to check whether the response was 
specific. As can be seen from Fig. 2 we achieved a good 
separation of immunoglobulins of autoimmune serum 
which correlated well with the standard separation [17]. 
The obtained Fab fragment of monoclonal antibody 
against topoisomerase I interacted only with the IgG 
fraction of the autoimmune serum (see Fig. 2). These 
data indicated that the response of the autoimmune 
serum to monoclonal antibodies was specific. Indeed, 
the response was associated with the variable part of the 
antibody and, moreover, Fab was bound to the IgG 
fraction. In the case of the rheumatoid factor, the inter- 
action is usually associated with the Fc fragment and 
the IgM fraction of the serum [ 111. 
All studied sera samp!es were also tested for the pres- 
ence of anti-DNA antibodies. The selected group with 
a high titer against the fusion protein and the monoclo- 
nal antibody against topoisomerase responded posi- 
tively as evidenced by the ELISA test. 
The sera exhibiting a positive response to antibodies 
against topoisomerase and DNA were passed through 
DNA- and antitopoisomerase-immobilized affinity col- 
68 
a 
Fig;. 2. SG+GtioC ~iG&iK~ USC! fcr -_.- . . . .._._ __._ -h*-;mm*an- 0-m immunoglobulins and MAB to check the specificity of their intcmction. (A) MPLC 
scpamtion of autoimmune scra. SDS-PAGE of sepnrated immunoglobuiins (MPLC fractions 1 and 3). m.wt. of protein standards on the left, ‘II’ 
heavy nnd ‘L’ light chains indicated on the right. (B) SDS-PAGE of MAB papain digest (on nhc right) Fab fmgmcnt of MAB following protein 
A Scpharose purification (on the left); m.wt. of protein standards indicated on the right. 
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3 
t 
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Autoimmune serum 
? 
Polyclonal antibodies to 
topoisomcrase I 
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I 
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t 
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Scheme 1. Flow diagram of isolation steps of topoisomerasc I anti- 
idiotypic antibodies. 
umns (see Scheme I). The fractions of antibodies ad- 
sorbed specifically onto the affinity supports were 
eluted and cross-analyzed. The DNA-eluted antibodies 
were shown to interact with monoclonal anti-topoisom- 
erase antibodies, whereas those eluted from the anti- 
topoisomerase column. gave a stable response to DNA 
binding. So our experiments have demonstrated that the 
sera from patients with autoimmune diseases, which 
respond positively to human topoisomerase contain 
anti-idiotypic antibodies possessing DNA binding ac- 
tivity. 
We studied the properties of isolated anti-idiotypes. 
The potency of these antibodies to compete with topoi- 
somerase for monoclonal antibody binding has been 
proven (see Fig. 3). The investigation of interaction be- 
A 
40% 
1.0 
<?.a 
0.6 
0.4 
0.2 
80 P8 
antfidiotypcs 
Fig. 3. Competition of anti-idiotypes and topoisomerase for MAB 
binding. 
Pig. 4, Determination of dissociation constants of DNA-topoisom- 
erase I complex (line 1) and DNA-anti-idiotypc antibody complex 
(line 2) using the method of Linewcavcr-Burk. 
tween topoisomerase I and anti-idiotypic antibodies 
with the fragment of the globin gene, containing consen- 
sus sequences pecific to topoisomerase I, was carried 
out. The data are shown in Fig. 4. Their analyses with 
the method of Lineweaver-Burk allowed to obtain dis- 
sociation constants of DNA-enzyme (1) and DNA- 
antibody (2) complexes. They were 0.13 nM and 0.27 
nM respectively. These data show that specific DNA 
sequences interact both with anti-idiotypes and topoi- 
somerase I, confirming the specific character of the anti- 
idiotype-DNA interaction. 
Studies on the specificity of these anti-idiotypes with 
respect o various DNA templates are now in progress 
in this laboratory. 
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